NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
methyl[(2R)-1-phenylpropan-2-yl](prop-2-yn-1-yl)amine hydrochloride
|
|
|
IUPAC Traditional name
|
selegiline hydrochloride
|
methyl[(2R)-1-phenylpropan-2-yl](prop-2-yn-1-yl)amine hydrochloride
|
|
|
Synonyms
|
(αR)-N,α-Dimethyl-N-2-propyn-1-yl-benzeneethanamine Hydrochloride
|
L-(-)-N,α-Dimethyl-N-2-propynylphenethylamine Hydrochloride
|
Antiparkin
|
Amindan
|
Selegiline
|
L-Deprenyl Hydrochloride
|
R-(-)-Deprenyl Hydrochloride
|
Eldepryl
|
L-Deprenyl
|
Zelapar
|
Anipryl
|
Selegiline hydrochloride
|
(R)-(-)-N,α-Dimethyl-N-(2-propynyl)phenethylamine hydrochloride
|
R(-)-N-α-Dimethyl-N-2-propynyl-benzeneethanamine hydrochloride
|
Selegiline hydrochloride
|
R-(-)-Deprenyl hydrochloride
|
Jumex
|
Tumex
|
Selegiline Hydrochloride
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
H Acceptors
|
1
|
H Donor
|
0
|
LogD (pH = 5.5)
|
-0.15821154
|
LogD (pH = 7.4)
|
1.5548966
|
Log P
|
2.847962
|
Molar Refractivity
|
61.3547 cm3
|
Polarizability
|
23.641752 Å3
|
Polar Surface Area
|
3.24 Å2
|
Rotatable Bonds
|
4
|
Lipinski's Rule of Five
|
true
|
DETAILS
DETAILS
Selleck Chemicals
Sigma Aldrich
TRC
Selleck Chemicals -
S1873
|
Research Area: Neurological Disease Biological Activity: Selegiline (Zelapar) is a selective, irreversible inhibitor of Type B monoamine oxidase used in newly diagnosed patients with Parkinson’s disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. The compound without isomeric designation is Deprenyl. [1] |
Sigma Aldrich -
M003
|
Biochem/physiol Actions Selective MAO-B inhibitor; anti-Parkinsonian agent. |
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • http://www.drugbank.ca/drugs/DB01037
- • Magyar, K., et al.: Acta Physiol. Acad. Sci. Hung., 32, 377 (1967)
- • Heinonen, E.H., et al.: Acta Neurol. Scand., 84, 44 (1967)
- • Schneider, L.S., et al.: Am. J. Psychiatry, 150, 321 (1967)
- • Fowler, J.S., J.O.C., 1977, 42, 2637, (synth, pmr)
- • Heinonen, E.H. et al., Acta Neurol. Scand., Suppl. 136, 1991, 84, 44, (pharmacol, rev)
- • Chrisp, P. et al., Drugs Aging, 1991, 1, 228, (rev)
- • Hermecz, I. et al., Acta Pharm. Hung., 1992, 62, 189; 237; 243, (rev)
- • Kudl, J., Pharmacol. Toxicol., 1992, 70, 317, (rev)
- • Elsworth, J.D. et al., Biog. Amines, 1993, 9, 381, (rev)
- • Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 849
- • Lange, K.W. et al., Clin. Pharmacol. Ther. (St. Louis), 1994, 56, 734, (pharmacol, rev)
- • Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, DAZ125
- • Swiss Pat., 1965, Dr A Wander, 393 306; CA, 64, 2004d, (synth)
- • Netherlands Pat., 1966, 6 605 956; CA, 67, 21611y, (synth)
- • Knoll, J., Ciba Found. Symp., 1976, 39, 135, (pharmacol)
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent